| Article Access Statistics|
| Viewed||2781 |
| Printed||91 |
| Emailed||0 |
| PDF Downloaded||403 |
| Comments ||[Add] |
Click on image for details.
| RESEARCH ARTICLE
|Year : 2016 | Volume
| Issue : 5 | Page : 503-508
A prospective, randomized study: Evaluation of the effect of rosuvastatin in patients with chronic obstructive pulmonary disease and pulmonary hypertension
Bharti Chogtu1, Sanitha Kuriachan1, Rahul Magazine2, K Ranjan Shetty3, Asha Kamath4, Manu Mathew George1, Amruta Tripathy1, D Mahesh Kumar1
1 Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India
2 Department of Pulmonary Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India
3 Department of Cardiology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India
4 Department of Community Medicine, Kasturba Medical College, Manipal University, Manipal, Karnataka, India
Objectives: Statins by their anti-inflammatory and endothelial stabilizing effect can be beneficial in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension (PH). The present study was done to evaluate the effect of rosuvastatin on pulmonary functions and quality of life (QOL) in patients with concomitant COPD and PH.
Materials and Methods: It was a prospective, randomized, double-blind, placebo-controlled, study conducted in patients with COPD and PH. A total of sixty patients were assigned to receive either rosuvastatin 10 mg or placebo once a day in addition to their conventional treatment for 12 weeks. Routine blood investigations, pulmonary functions, echocardiogram, exercise capacity, and QOL using a questionnaire were assessed at the baseline and after 12 weeks.
Results: In patients of rosuvastatin group, there was a statistically significant increase in peak expiratory flow rate (PEFR) (P = 0.04) but no significant change in other pulmonary functions: Forced vital capacity (FVC), forced expiratory volume at 1 s (FVC, FEV 1 , FEV 1 /FVC), and echocardiogram parameters. There was a significant increase in 6-min walk test (6-min walk distance) (P = 0.03) at the end of 12 weeks. On comparing with placebo, rosuvastatin showed a significant reduction (P = 0.045) in COPD exacerbations while adverse effects did not differ.
Conclusion: Statins have a favorable effect on patients with COPD and PH regarding the improvement in PEFR, COPD exacerbations, and exercise capacity. Such effects can be beneficial in these patients and more so in patients with concomitant coronary artery disease or hyperlipidemia where long-term benefits of statins have been established.
Dr. Bharti Chogtu
Department of Pharmacology, Kasturba Medical College, Manipal University, Manipal, Karnataka
Source of Support: None, Conflict of Interest: None
Clinical trial registration CTRI/2012/12/003223 (Registered on 17/12/2012)
[FULL TEXT] [PDF]*